Published in Front Biosci on May 01, 2007
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 5.54
Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol (2008) 2.41
Cancer systems biology: a network modeling perspective. Carcinogenesis (2009) 2.22
Nonlinear modelling of cancer: bridging the gap between cells and tumours. Nonlinearity (2010) 2.08
A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One (2010) 1.83
Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia (2011) 1.56
Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res Treat (2009) 1.55
Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells. Cell Cycle (2011) 1.46
Activation of host wound responses in breast cancer microenvironment. Clin Cancer Res (2009) 1.45
Three-dimensional multispecies nonlinear tumor growth-II: Tumor invasion and angiogenesis. J Theor Biol (2010) 1.37
Multiparameter computational modeling of tumor invasion. Cancer Res (2009) 1.28
Stemming cancer: functional genomics of cancer stem cells in solid tumors. Stem Cell Rev (2008) 1.22
Scratching the niche that controls Caenorhabditis elegans germline stem cells. Semin Cell Dev Biol (2009) 1.22
Tumor exosomes induce tunneling nanotubes in lipid raft-enriched regions of human mesothelioma cells. Exp Cell Res (2014) 1.17
Overexpression of REIC/Dkk-3 in normal fibroblasts suppresses tumor growth via induction of interleukin-7. J Biol Chem (2009) 1.17
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol (2012) 1.12
Genome-wide gene expression analysis in cancer cells reveals 3D growth to affect ECM and processes associated with cell adhesion but not DNA repair. PLoS One (2012) 1.10
Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discovery. Cell Cycle (2013) 1.07
Tumor stroma as targets for cancer therapy. Pharmacol Ther (2012) 1.06
Oncogenic H-ras reprograms Madin-Darby canine kidney (MDCK) cell-derived exosomal proteins following epithelial-mesenchymal transition. Mol Cell Proteomics (2013) 1.04
Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. Cancer Res (2012) 1.02
Fibronectin extra domain A (EDA) sustains CD133(+)/CD44(+) subpopulation of colorectal cancer cells. Stem Cell Res (2013) 1.00
Exosomes in Cancer Microenvironment and Beyond: have we Overlooked these Extracellular Messengers? Cancer Microenviron (2012) 0.99
Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts. Neoplasia (2013) 0.98
Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol (2010) 0.97
Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFκB target stromal MCT4. Cell Cycle (2013) 0.97
The epigenetic influence of tumor and embryonic microenvironments: how different are they? Cancer Microenviron (2008) 0.97
Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol (2015) 0.97
Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis. PLoS One (2011) 0.96
Histological and molecular aspects of oral squamous cell carcinoma (Review). Oncol Lett (2014) 0.96
A role for the epithelial microenvironment at tumor boundaries: evidence from Drosophila and human squamous cell carcinomas. Am J Pathol (2010) 0.95
Feedback within the inter-cellular communication and tumorigenesis in carcinomas. PLoS One (2012) 0.95
Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis. Cancer Res (2009) 0.95
Remodeling of purinergic receptor-mediated Ca2+ signaling as a consequence of EGF-induced epithelial-mesenchymal transition in breast cancer cells. PLoS One (2011) 0.90
Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol (2015) 0.90
Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-gamma Ligands in Lung Cancer. PPAR Res (2008) 0.89
Molecular regulation of tumor angiogenesis and perfusion via redox signaling. Chem Rev (2009) 0.89
Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice. PLoS One (2010) 0.89
Extracellular matrix-induced gene expression in human breast cancer cells. Mol Cancer Res (2009) 0.88
Intercellular communication in malignant pleural mesothelioma: properties of tunneling nanotubes. Front Physiol (2014) 0.88
The role of the microenvironment in tumor immune surveillance. Bioinformation (2011) 0.88
Genomics and proteomics approaches to the study of cancer-stroma interactions. BMC Med Genomics (2010) 0.87
What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us? BMC Med (2011) 0.86
Long-range gap junctional signaling controls oncogene-mediated tumorigenesis in Xenopus laevis embryos. Front Physiol (2015) 0.86
Exploiting the tumor microenvironment for theranostic imaging. NMR Biomed (2011) 0.85
Chondroitin sulfate-E is a negative regulator of a pro-tumorigenic Wnt/beta-catenin-Collagen 1 axis in breast cancer cells. PLoS One (2014) 0.84
Perspectives on reprograming cancer-associated dendritic cells for anti-tumor therapies. Front Oncol (2014) 0.84
Tumor cells derived exosomes contain hTERT mRNA and transform nonmalignant fibroblasts into telomerase positive cells. Oncotarget (2016) 0.83
FH535 inhibited migration and growth of breast cancer cells. PLoS One (2012) 0.83
From integrative genomics to therapeutic targets. Cancer Res (2013) 0.83
Eicosanoid profiling in an orthotopic model of lung cancer progression by mass spectrometry demonstrates selective production of leukotrienes by inflammatory cells of the microenvironment. PLoS One (2013) 0.82
Expression profiles of SnoN in normal and cancerous human tissues support its tumor suppressor role in human cancer. PLoS One (2013) 0.81
Sirt1 Is Required for Resveratrol-Mediated Chemopreventive Effects in Colorectal Cancer Cells. Nutrients (2016) 0.79
Expression Profiling of Macrophages Reveals Multiple Populations with Distinct Biological Roles in an Immunocompetent Orthotopic Model of Lung Cancer. J Immunol (2016) 0.79
Nicotinamide, NAD(P)(H), and Methyl-Group Homeostasis Evolved and Became a Determinant of Ageing Diseases: Hypotheses and Lessons from Pellagra. Curr Gerontol Geriatr Res (2012) 0.78
Loss of Dab2 expression in breast cancer cells impairs their ability to deplete TGF-β and induce Tregs development via TGF-β. PLoS One (2014) 0.78
Liquid-based three-dimensional tumor models for cancer research and drug discovery. Exp Biol Med (Maywood) (2016) 0.78
Wharton's Jelly-Derived Mesenchymal Stromal Cells and Fibroblast-Derived Extracellular Matrix Synergistically Activate Apoptosis in a p21-Dependent Mechanism in WHCO1 and MDA MB 231 Cancer Cells In Vitro. Stem Cells Int (2016) 0.77
Anti- and Protumorigenic Effects of PPARγ in Lung Cancer Progression: A Double-Edged Sword. PPAR Res (2012) 0.77
Mammographic density as a predictor of breast cancer outcome. Future Oncol (2010) 0.77
Adhesion to substrates induces dendritic cell endothelization and decreases immunological response. Immunobiology (2012) 0.77
Architecture Is the Message: The role of extracellular matrix and 3-D structure in tissue-specific gene expression and breast cancer. Pezcoller Found J (2007) 0.77
Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment. J Immunol (2015) 0.76
From competency to dormancy: a 3D model to study cancer cells and drug responsiveness. J Transl Med (2016) 0.75
Molecular mechanism of the "feedback loop" model of carcinogenesis. Commun Integr Biol (2012) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol (2005) 13.98
Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 13.79
The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15
Putting tumours in context. Nat Rev Cancer (2001) 12.37
TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 10.23
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res (1999) 8.63
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol (2002) 8.27
Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med (2006) 7.89
Aspirin use and reduced risk of fatal colon cancer. N Engl J Med (1991) 7.85
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (1997) 7.66
Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci U S A (1975) 7.27
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature (2005) 7.24
Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A (1994) 6.48
The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell (1999) 6.08
Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med (1994) 5.42
Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 5.27
Stromal effects on mammary gland development and breast cancer. Science (2002) 5.22
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther (2000) 5.09
Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet (2005) 4.33
Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol (1997) 4.22
Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev (2005) 4.05
Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood (2004) 3.59
Prostaglandins and cancer. Gut (2005) 3.44
Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet (2002) 3.35
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer (2006) 3.19
Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol (2005) 3.19
Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res (2000) 3.06
Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. Exp Cell Res (2005) 2.62
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene (2005) 2.35
Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci U S A (1990) 2.34
Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol (2004) 2.19
Inability of Rous sarcoma virus to cause sarcomas in the avian embryo. Nature (1984) 2.18
Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer (2006) 2.09
Mesenchyme-dependent morphogenesis and epithelium-specific cytodifferentiation in mouse mammary gland. Science (1976) 2.08
Wounding and its role in RSV-mediated tumor formation. Science (1985) 1.93
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res (2005) 1.80
Inhibition of TGFbeta signaling in cancer therapy. Curr Opin Genet Dev (2005) 1.78
Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res (2006) 1.67
Induction of embryonic primordia by implantation of organizers from a different species. 1923. Int J Dev Biol (2001) 1.62
Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A (2005) 1.51
Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol (2004) 1.43
Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol (2002) 1.41
Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol (2003) 1.33
CYTODIFFERENTIATION AND ITS CONTROLS. Science (1964) 1.32
Breast cancer: induction of differentiation by embryonic tissue. Science (1973) 1.27
Signals which build a tubule. Nephron Exp Nephrol (2005) 1.26
The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Ther (2000) 1.21
The tumor-promoting effect of wounding: a possible role for TGF-beta-induced stromal alterations. Crit Rev Oncog (1994) 1.21
Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res (2006) 1.12
Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev (2005) 1.11
Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer (2006) 1.06
Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta Pharmacol Sin (2005) 1.03
Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible? J Steroid Biochem Mol Biol (1997) 1.00
Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. J Clin Endocrinol Metab (1997) 1.00
Anti-tumour activity of zoledronic acid. Cancer Treat Rev (2005) 0.96
Dichotomies in cancer research: some suggestions for a new synthesis. Nat Clin Pract Oncol (2006) 0.90
Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12. J Gastroenterol Hepatol (2004) 0.83
Moving into the future: treatment of bone metastases and beyond. Cancer Treat Rev (2005) 0.81
Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods (2007) 7.43
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature (2005) 7.24
Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol (2006) 6.64
Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev (2002) 6.55
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol (2007) 5.81
beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell (2002) 5.56
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46
Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J Cell Sci (2002) 4.25
Tissue geometry determines sites of mammary branching morphogenesis in organotypic cultures. Science (2006) 4.12
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Evidence for a stem cell hierarchy in the adult human breast. J Cell Biol (2007) 3.76
Modeling tissue-specific signaling and organ function in three dimensions. J Cell Sci (2003) 3.52
Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst (2002) 3.39
The perivascular niche regulates breast tumour dormancy. Nat Cell Biol (2013) 3.36
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes. Breast Cancer Res (2003) 3.13
Tumor reversion: correction of malignant behavior by microenvironmental cues. Int J Cancer (2003) 3.02
Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. J Cell Biol (2004) 2.93
Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res (2006) 2.86
Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis. J Cell Biol (2003) 2.68
Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell (2012) 2.61
MYC suppresses cancer metastasis by direct transcriptional silencing of αv and β3 integrin subunits. Nat Cell Biol (2012) 2.61
Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin Cancer Biol (2005) 2.53
Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol (2008) 2.41
Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci U S A (2006) 2.41
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat (2009) 2.34
Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J Cell Biochem (2007) 2.32
Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest (2007) 2.29
Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol (2008) 2.18
Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS One (2008) 2.12
Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol (2003) 2.06
The MAPK(ERK-1,2) pathway integrates distinct and antagonistic signals from TGFalpha and FGF7 in morphogenesis of mouse mammary epithelium. Dev Biol (2007) 1.98
Tissue architecture and function: dynamic reciprocity via extra- and intra-cellular matrices. Cancer Metastasis Rev (2009) 1.93
Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. J Mammary Gland Biol Neoplasia (2005) 1.92
Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res (2008) 1.83
Human mammary progenitor cell fate decisions are products of interactions with combinatorial microenvironments. Integr Biol (Camb) (2008) 1.82
The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem (2007) 1.82
A human breast cell model of preinvasive to invasive transition. Cancer Res (2008) 1.79
The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat (2012) 1.77
Laminin and biomimetic extracellular elasticity enhance functional differentiation in mammary epithelia. EMBO J (2008) 1.74
The dominance of the microenvironment in breast and ovarian cancer. Semin Cancer Biol (2002) 1.73
Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res (2006) 1.69
Myoepithelial cells: good fences make good neighbors. Breast Cancer Res (2005) 1.66
A role for dystroglycan in epithelial polarization: loss of function in breast tumor cells. Cancer Res (2002) 1.65
Cell shape regulates global histone acetylation in human mammary epithelial cells. Exp Cell Res (2007) 1.64
Cancer. Respect thy neighbor! Science (2004) 1.62
Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition. Cancer Res (2007) 1.60
Breast cancer by proxy: can the microenvironment be both the cause and consequence? Trends Mol Med (2008) 1.60
Evidence for formation of DNA repair centers and dose-response nonlinearity in human cells. Proc Natl Acad Sci U S A (2011) 1.58
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res (2011) 1.56
Extracellular matrix control of mammary gland morphogenesis and tumorigenesis: insights from imaging. Histochem Cell Biol (2008) 1.55
Dystroglycan loss disrupts polarity and beta-casein induction in mammary epithelial cells by perturbing laminin anchoring. J Cell Sci (2006) 1.49
Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. PLoS Comput Biol (2010) 1.46
Extracellular matrix-regulated gene expression requires cooperation of SWI/SNF and transcription factors. J Biol Chem (2007) 1.46
Coherent angular motion in the establishment of multicellular architecture of glandular tissues. Proc Natl Acad Sci U S A (2012) 1.45
Sustained activation of STAT5 is essential for chromatin remodeling and maintenance of mammary-specific function. J Cell Biol (2009) 1.44
Change in cell shape is required for matrix metalloproteinase-induced epithelial-mesenchymal transition of mammary epithelial cells. J Cell Biochem (2008) 1.41
Self-organization of engineered epithelial tubules by differential cellular motility. Proc Natl Acad Sci U S A (2009) 1.36
Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. Proc Natl Acad Sci U S A (2012) 1.36
Three-dimensional lithographically defined organotypic tissue arrays for quantitative analysis of morphogenesis and neoplastic progression. Nat Protoc (2008) 1.35
Proteolytic enzymes and altered glycosylation modulate dystroglycan function in carcinoma cells. Cancer Res (2004) 1.33
Is CD133 a marker of metastatic colon cancer stem cells? J Clin Invest (2008) 1.32
Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res (2010) 1.32
Rhamm-/- fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair. J Cell Biol (2006) 1.28
Collagen-IV and laminin-1 regulate estrogen receptor alpha expression and function in mouse mammary epithelial cells. J Cell Sci (2003) 1.27
Three-dimensional culture of human breast epithelial cells: the how and the why. Methods Mol Biol (2013) 1.26
Transmembrane/cytoplasmic, rather than catalytic, domains of Mmp14 signal to MAPK activation and mammary branching morphogenesis via binding to integrin β1. Development (2013) 1.23
Rap1 integrates tissue polarity, lumen formation, and tumorigenic potential in human breast epithelial cells. Cancer Res (2007) 1.22
Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. Proc Natl Acad Sci U S A (2012) 1.21
Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol (2012) 1.20
Dissecting regional variations in stress fiber mechanics in living cells with laser nanosurgery. Biophys J (2010) 1.20
To create the correct microenvironment: three-dimensional heterotypic collagen assays for human breast epithelial morphogenesis and neoplasia. Methods (2003) 1.19
p53-dependent integration of telomere and growth factor deprivation signals. Proc Natl Acad Sci U S A (2007) 1.18
The organization of tight junctions in epithelia: implications for mammary gland biology and breast tumorigenesis. J Mammary Gland Biol Neoplasia (2003) 1.18
Delivering the message: epimorphin and mammary epithelial morphogenesis. Trends Cell Biol (2003) 1.18
Higher-order nuclear organization in growth arrest of human mammary epithelial cells: a novel role for telomere-associated protein TIN2. J Cell Sci (2005) 1.17
Depletion of nuclear actin is a key mediator of quiescence in epithelial cells. J Cell Sci (2011) 1.16
Order and disorder: the role of extracellular matrix in epithelial cancer. Cancer Invest (2002) 1.15
Epithelial progenitor cell lines as models of normal breast morphogenesis and neoplasia. Cell Prolif (2003) 1.15
Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo. Genes Dev (2010) 1.14
The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin. Breast Cancer Res Treat (2011) 1.14
Chromatin organization measured by AluI restriction enzyme changes with malignancy and is regulated by the extracellular matrix and the cytoskeleton. Am J Pathol (2005) 1.14
Cytoplasmic SnoN in normal tissues and nonmalignant cells antagonizes TGF-beta signaling by sequestration of the Smad proteins. Proc Natl Acad Sci U S A (2005) 1.14
Of microenvironments and mammary stem cells. Stem Cell Rev (2007) 1.14
Automated local bright feature image analysis of nuclear protein distribution identifies changes in tissue phenotype. Proc Natl Acad Sci U S A (2006) 1.13
Tumor engineering: the other face of tissue engineering. Tissue Eng Part A (2010) 1.12
Single proteins might have dual but related functions in intracellular and extracellular microenvironments. Nat Rev Mol Cell Biol (2009) 1.12
Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways. J Clin Invest (2013) 1.11
Extracellular matrix, nuclear and chromatin structure, and gene expression in normal tissues and malignant tumors: a work in progress. Adv Cancer Res (2007) 1.11
Self-organization is a dynamic and lineage-intrinsic property of mammary epithelial cells. Proc Natl Acad Sci U S A (2011) 1.11
IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells. Sci Transl Med (2011) 1.11
Patterned collagen fibers orient branching mammary epithelium through distinct signaling modules. Curr Biol (2013) 1.09
Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo. Mol Cancer Ther (2009) 1.09
The hemopexin domain of MMP3 is responsible for mammary epithelial invasion and morphogenesis through extracellular interaction with HSP90β. Genes Dev (2013) 1.08
Interaction of E-cadherin and PTEN regulates morphogenesis and growth arrest in human mammary epithelial cells. Cancer Res (2009) 1.08
Localization of plasma membrane and secretory calcium pumps in the mammary gland. Biochem Biophys Res Commun (2008) 1.06
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. J Clin Invest (2012) 1.06